Professional Documents
Culture Documents
1
March 2013
___________________________________________________________________________
World Health Organization 2013
All rights reserved.
1.
Introduction................................................................................................................3
2.
3.
4.
References................................................................................................................20
Introduction
Questions to pharmacopoeias
Name of pharmacopoeia
2.
3.
4.
5.
6.
8.
Collaboration with and/or being part of a (different) national/regional pharmacopoeia if yes, which?
9.
10.
11.
National :
Croatia
Name of
pharmacopoeia
The International
Pharmacopoeia
Europe
European
Pharmacopoeia
(Ph. Eur.)
Europe
Hrvatska Farmakopeja
Update frequency
Latest edition
Year
Annually
2006
2011
2010
2012
Croatian
Pharmacopoeia with
comments
Edition (MMIX)
Supplement
2007
2012
Name of
pharmacopoeia
Update frequency
Latest edition
Year
Ph. Eur.
France
Pharmacope franaise
Germany
(see
Ph. Eur.)
April
2012
Sweden
Deutsches Arzneibuch
(DAB)
Farmacopeia Portuguesa Published every 4 years,
with 3 supplements
annually
Yugoslav
N/A
Pharmacopoeia
Real Farmacopea
Planned to follow the same
Espaola
frequency as the Ph. Eur.
Ph. Eur.
(see Ph. Eur.)
Switzerland
United
Kingdom (UK)
National:
Kazakhstan (Ph.
Eur. Obs.)
British Pharmacopoeia
Portugal
Serbia
Spain
Russian
Federation (Ph.
Eur. Obs.)
Ukraine (Ph.
Eur. Obs.)
National:
China (Ph. Eur.
Obs.) *
India
Indonesia
Farmakope Indonesia
Japan
The Japanese
Pharmacopoeia (JP)
Korea*
Annually
The Korean
Pharmacopoeia
National:
North America
United States of United States
America
Pharmacopeia (USP)
(Ph. Eur. Obs.)
National:
Latin America
Argentina
Farmacopea Argentina
(Ph. Eur. Obs.)
9th Edition,
Vol. 1,Vol. 2,Vol. 3
Supplement 9.8
Translation of Ph. Eur.
3rd Ed.
4th Edition
(see Ph. Eur.)
10th Edition
Supplement 10.3
BP
2011
2008
2010
1997
2011
(see
Ph. Eur.)
2006
2010
2013
1st Edition
1, 2 volumes
2008
2007
Bianually
1st Edition
Supplement 4
2001
2011
9th Edition
2010
2010
2012
Annually, with 2
supplements per year
USP 35-NF 30
Supplement
2011
2012
Undetermined, intended
bianually
8th Edition*
(vol.1,2,3,4)
2011
1995
2011
2011
2012
2007
2011
Name of
pharmacopoeia
Update frequency
Latest edition
Year
Farmacopia Brasileira
No defined periodicity
2010
Annual update
10th Edition
Supplement
2011
2012
Farmacopea de los
Estados Unidos
Mexicanos
(Ph. Eur. Obs.) = Ph. Eur. Observer
* Not represented at the meeting.
Pharmacopoeia referred to in
national/regional legislations
Not applicable
Czech Republic
France
Germany
Serbia
Spain
Sweden
Switzerland
UK
National:
Kazakhstan
(Ph. Eur. Obs.)
Russian
Federation
Pharmacopoeia referred to in
national/regional legislations
(Act on Pharmaceuticals)
National legislation (Code de la sant publique: Art. L. 5112-1). Overseas
See under
traditional pharmacopeia subject to regulatory conformities (departments:
EU
Caribbean, Guyana, Reunion Island and territories, French Polynesia,
Caledonia)
Medicinal Products Act (The Drug Law) Arzneimittelgesetz (AMG) of the
National:
India
Indonesia
Japan
Korea**
National:
United States
(Ph. Eur. Obs.)
National:
Argentina
(Ph. Eur. Obs.)
Pharmacopoeia referred to in
national/regional legislations
Asia
Drugs & Cosmetic Act 1949 and Rules 1945.
IP is published by the Indian Pharmacopoeia
Commission, the Standards Setting Institution
for Drugs. It is an autonomous body under the
Ministry of Health & Family Welfare.
Act of The Republic of Indonesia Number 36
Year 2009 on Health (Revised Act of The
Republic of Indonesia Number 23 Year 1992)
Article105
Art. 3: The products covered by this law shall satisfy the conditions laid down in the Pharmacopoeia Argentina and, if not
included in it, the conditions which arise from international standards and texts of recognized scientific value.
Pharmacopoeia referred to in
national/regional legislations
For example, monographs for Blood Products were presented by Argentina (12), Brazil
(20) and India (21), while monographs for Vaccines were presented by Argentina (21),
India (57), Kazakhstan (15) and Ukraine (26). Homeopathic preparations described in
monographs were presented mainly by France (320), Germany (120) and Mexico (558)
and finally Monographs for Traditional Medicine were given as an example by China
(2165). A total of 92 herbal, traditional herbal and homeopathic monographs are present in
the British Pharmacopoeia 2012. Supplementary information is included in some of the
pharmacopoeias, for example general texts, reference tables, and texts on methods of
analysis, reagents, materials/containers, sutures, and references substance used in national
monographs.
Detailed information as provided at the meeting or sent to WHO is summarized in Table 3.
Table 3. Number of monographs included in pharmacopoeias
Scope
Organization,
region or
country
International
WHO (Ph. Int.)
Regional
EU (Ph. Eur.)
National
Croatia
Czech Rep.
France
Germany
Portugal
Serbia
Spain
Sweden
APIs+
excipients
Finished dosage
forms
Biologicals
441
141
N/S**
82
14
N/S***
30
295
22
3210
N/S
Ph. Eur
118
Ph. Eur.+4
N/S
85
Ph. Eur.
N/S
Ph. Eur.
Ph.Eur.
0
5
N/S
Ph. Eur.
Ph.Eur.
N/S
Ph. Eur.
Ph. Eur
2
3
N/S
Ph. Eur.
Ph.Eur.
300
Ph. Eur.
N/S
17
N/S
N/S
Ph. Eur.
Ph.Eur.
N/S
Ph. Eur.
N/S
N/S
115
N/S
N/S
N/S
N/S
N/S
1850
Europe
Ph. Eur
36
53
91
Ph. Eur.
Ph.Eur
3000
Ph. Eur.
General
Supplemonographs mentary
+ methods information
Herbal
products
APIs+
excipients
Finished dosage
forms
Ph. Eur.
Ph. Eur.+171
Ph. Eur.
Ph. Eur.+1431
Eastern
Europe
300
77
326
Asia
733
806
560
N/S
1222
877
Biologicals
Ph. Eur.
196
General
Supplemonographs mentary
+ methods information
Ph. Eur.
incl.in finished
dosage forms
Herbal
products
Ph. Eur.
73
N/S
98
N/S
N/S
24
221
187
79
N/S
18
N/S
26
88
104
1366
838
653
591
542
421
131
91
29
N/S
64
39
152
18
23
N/S
N/S
N/S
N/S
223
1
N/S
39
N/S
N/S
93
N/S
N/S
N/S
181
North
America
United States
1848
2454
153
300
N/S
N/S
National
South
America
Argentina
496
254
18
92
18
29
Brazil
284
207
51
110
N/S
58
Mexico
649
626
75
191
N/S
75
Notes: N/S not specified in countrys response
* Country not represented at the meeting, information sent to WHO.
** Part of activities of the WHO Expert Committee on Biological Standardization.
*** Part of the Traditional Medicine Programme, and published in Quality control methods for herbal
materials, Geneva, World Health Organization, 2011.
Ph. Int. commits to fulfilling the mandate of WHO given by its Member States and
responds to the needs of the latter. As an international body, it also responds to the needs
of quality control laboratories for post-marketing surveillance and maintains the
international applicability of Ph. Int. specifications. Keeping the costs of analysis in mind,
especially in the case of developing countries, Ph. Int. provides standards for major public
health needs.
European Union
Ph. Eur. supports innovation and flexibility without losing the aim of a pharmacopoeia (i.e.
to provide official, recognized and technically sound quality standards), e.g. PAT, NIR and
acceptance criteria for large sample sizes. It also remains at the forefront in the biofield
(e.g. P4Bio) and constantly increases harmonization with pharmacopoeias by
collaboration, i.e. as part of PDG, and maintains observers within other pharmacopoeial
institutions worldwide.
Ph. Eur. Member States Sweden and Finland continue to cooperate and to be active in the
elaboration of the Ph. Eur.
Croatia is currently preparing a publication of a new edition of the Croatian
Pharmacopoeia.
The Czech Republic would like to complete a national formulary, mainly in the field of
paediatrics by cooperation with a chamber of paediatricians; assessment of stabilities in the
pharmacopoeia formularies for small-scale products and products prepared in pharmacies
have also been mentioned as a future plan by Czech representatives, i.e. establishment of a
new group of experts from hospital pharmacies and certified laboratories.
France presented its strategy for the future at both the national and European levels.
Publication online (and revisions: REACH, DCF), defines new policy and reinforces the
code of practices in line with the new French Public Health Law; it defines the work
programme based on both interest of patients or professionals (paediatric, ophthalmic and
homeopathic preparations) and conforms to regulation and national strategy (French
overseas territories). As a key player within the Ph. Eur., France would like to contribute
its share of specific topics such as biological products, cell and tissue, allergenic products,
antiseptic preparations, paediatric preparations, traditional herbal preparations (TCM) and
collaboration with OMCLs work programme (MMS) and P4 procedures.
In addition to its contributions to the Ph. Eur. Germany focuses on particular technical
issues in terms of pharmaceutical analysis such as identification of materials by the
evaluation of analytical fingerprints, use of non-destructive spectroscopic methods,
imaging techniques for the intact pharmaceutical preparations, trace analysis of impurities
and simplified analytical identification tests for certified substances.
As a country collaborating closely with the Ph. Eur. Portugal focuses on its future plan to
update national texts, to tighten the links with Portuguese-speaking countries and with
stakeholders (regulators, manufacturers of APIs and manufacturers of medicines).
Serbia will prepare its national addition to Ph. Eur., update national Magistral
Formularies and continue cooperation with the Ph. Eur. as a member.
Spain plans to follow the timetable of publication of the in-force Ph. Eur. successive
editions (simultaneous translation), to work with internal Spanish groups that support the
work of the experts and specialists in European and international groups and continue its
efforts to cooperate with the work of the Ph. Eur. and international groups (groups of
experts, working parties).
Switzerland focuses on participation in the activities of the Ph. Eur. in the framework of
the legally binding mandate of the Ph. Eur. Convention.
Asia
Japans tendencies for internationalization of its pharmacopoeia are based on prompt
publication and further improvement of the JP English Edition and Home Page. Building
up of the frameworks for international information exchange among pharmacopoeias
should also be intensified. For its next revision JP commits itself to follow-up of the
revision of General Rules for Preparations in JP16: general quality tests for preparations
would be newly set, to revise containers and storage and to create a new framework for
monographs of drugs, whose manufacturing processes are different, including impurities
(including residual solvents), process-related substances, impurities in biotech-products
and tests for preparations.
China provided information to WHO stating that the country is committed to more
cooperation with other world leading pharmacopoeias.
India, in terms of sharing of information among pharmacopoeias, would like to focus on
resources, working in pockets where there is a need for sharing information and providing
commitment to monitoring, harmonization with leading pharmacopoeias and also
providing quality medicines through harmonized drug standards and monitoring quality of
medicines through an effective regulatory system.
Indonesia's plans are to publish a new edition of the Indonesian Pharmacopoeia every five
years, to publish the supplement annually for the existing pharmacopoeia and to publish
the pharmacopoeia in an English version.
Korea informed WHO that it aims to include in its pharmacopoeia all medicines which are
relevant from the viewpoint of health care and medical treatment, to revise it in timely
fashion in part, if necessary, for efficient application, to follow international harmonization,
to ensure transparency regarding the revision of the Korean Pharmacopoeia, to render the
References
1.
2.
Index of Pharmacopoeias
http://www.who.int/medicines/areas/quality_safety/quality_assurance/resources/ind
ex-of-pharmacopoeias16032012.pdf.
3.
4.